Clinical trial
Prevention Of Recurrence Of Atrial Fibrillation
NCT00041496 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00041496 |
|---|---|
| Title | Prevention Of Recurrence Of Atrial Fibrillation |
| Official title | A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fibrillation, Atrial |
| Intervention type | Drug, Other |
| Interventions | SB-207266, Placebo |
| Enrollment | 520 |
| Start date | Nov 1, 2001 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Jul 12, 2002 |
| Last update posted | Aug 11, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: